Artemether
Coartem (artemether) is a small molecule pharmaceutical. Artemether was first approved as Coartem on 2009-04-07. It is used to treat falciparum malaria and malaria in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Combinations
Coartem
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Artemether
+
Lumefantrine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| COARTEM | Novartis | N-022268 RX | 2009-04-07 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| coartem | New Drug Application | 2020-06-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| falciparum malaria | EFO_0007444 | D016778 | B50 |
| malaria | EFO_0001068 | D008288 | B54 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
350 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 16 | 37 | 79 | 25 | 16 | 169 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 12 | 34 | 54 | 46 | 7 | 150 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | 4 | 4 | — | 8 |
| Disease progression | D018450 | — | — | 1 | 3 | 2 | 6 | ||
| Chronic bronchitis | D029481 | J42 | — | — | 2 | 3 | — | 5 | |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | 1 | 1 | 1 | 3 |
| Exercise-induced asthma | D001250 | J45.990 | — | 1 | 1 | 1 | — | 3 | |
| Exercise | D015444 | EFO_0000483 | — | — | — | 1 | 1 | 2 | |
| Bronchitis | D001991 | J40 | — | — | 1 | 1 | — | 2 | |
| Asthma-chronic obstructive pulmonary disease overlap syndrome | D000080445 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 2 | 1 | — | — | 2 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | — | — | 1 |
| Hypoxia | D000860 | R09.02 | — | — | 1 | — | — | 1 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 1 | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | 1 | — | — | 1 | |
| Smoking | D012907 | EFO_0003768 | F17 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Medication adherence | D055118 | EFO_0006344 | 2 | 2 | — | — | — | 2 | |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans | D001989 | EFO_0007183 | — | 1 | — | — | — | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Airway obstruction | D000402 | — | 1 | — | — | — | 1 | ||
| Inflammation | D007249 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Personal satisfaction | D010549 | — | — | — | — | 1 | 1 | ||
| Patient satisfaction | D017060 | — | — | — | — | 1 | 1 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | 1 | 1 | ||
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ARTEMETHER |
| INN | artemether |
| Description | Artemether is an artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. It has a role as an antimalarial. It is a sesquiterpenoid, a cyclic acetal, an organic peroxide, an artemisinin derivative and a semisynthetic derivative. |
| Classification | Small molecule |
| Drug class | antimalarials (artemisin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3 |
Identifiers
| PDB | — |
| CAS-ID | 71963-77-4 |
| RxCUI | 18343 |
| ChEMBL ID | CHEMBL566534 |
| ChEBI ID | 195280 |
| PubChem CID | 68911 |
| DrugBank | DB06697 |
| UNII ID | C7D6T3H22J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,923 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,465 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more